These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 9697721)

  • 41. Human immunodeficiency virus type 1 protease inhibitors.
    McDonald CK; Kuritzkes DR
    Arch Intern Med; 1997 May; 157(9):951-9. PubMed ID: 9140265
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targets of a protease inhibitor, KNI-272, in HIV-1-infected cells.
    Goto T; Nakano T; Kohno T; Morimatsu S; Morita C; Hong W; Kiso Y; Nakai M; Sano K
    J Med Virol; 2001 Mar; 63(3):203-9. PubMed ID: 11170058
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Saquinavir-mediated inhibition of human immunodeficiency virus (HIV) infection in SCID mice implanted with human fetal thymus and liver tissue: an in vivo model for evaluating the effect of drug therapy on HIV infection in lymphoid tissues.
    Pettoello-Mantovani M; Kollmann TR; Raker C; Kim A; Yurasov S; Tudor R; Wiltshire H; Goldstein H
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1880-7. PubMed ID: 9303378
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synergistic antiviral effect of PEG-asparaginase (ONCASPAR), with protease inhibitor alone and in combination with RT inhibitors against HIV-1 infected T-cells: a model of HIV-1-induced T-cell lymphoma.
    Avramis VI; Kwock R; Avramis IA; Cohen LJ; Inderlied C
    In Vivo; 2001; 15(1):1-9. PubMed ID: 11286117
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.
    Nagy K; Young M; Baboonian C; Merson J; Whittle P; Oroszlan S
    J Virol; 1994 Feb; 68(2):757-65. PubMed ID: 8289379
    [TBL] [Abstract][Full Text] [Related]  

  • 46. APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro.
    Pereira CF; Paridaen JT; van de Bovenkamp M; Middel J; Verhoef J; Nottet HS
    J Antimicrob Chemother; 2003 May; 51(5):1181-9. PubMed ID: 12668583
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.
    Robinson BS; Riccardi KA; Gong YF; Guo Q; Stock DA; Blair WS; Terry BJ; Deminie CA; Djang F; Colonno RJ; Lin PF
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2093-9. PubMed ID: 10898681
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Susceptibilities of simian immunodeficiency virus to protease inhibitors.
    Giuffre AC; Higgins J; Buckheit RW; North TW
    Antimicrob Agents Chemother; 2003 May; 47(5):1756-9. PubMed ID: 12709355
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Correlation between HIV-inhibiting drug activity in human macrophages and clinical outcome].
    Aquaro S; Balestra E; Panti S; Cenci A; Serra F; Francesconi M; Abdelahad D; Caliò R; Perno CF
    Clin Ter; 1998; 149(921):37-41. PubMed ID: 9621487
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of a human immunodeficiency virus protease inhibitor on human monocyte function.
    Bugelski PJ; Kaplan JM; Hart TK; Miller J; Laydon JT; Lee JC; Dreyer GB; Kirsh R
    AIDS Res Hum Retroviruses; 1992 Dec; 8(12):1951-8. PubMed ID: 1493045
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
    Shiraki N; Hamada A; Yasuda K; Fujii J; Arimori K; Nakano M
    Biol Pharm Bull; 2000 Dec; 23(12):1528-31. PubMed ID: 11145192
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors.
    Phenix BN; Angel JB; Mandy F; Kravcik S; Parato K; Chambers KA; Gallicano K; Hawley-Foss N; Cassol S; Cameron DW; Badley AD
    AIDS Res Hum Retroviruses; 2000 Apr; 16(6):559-67. PubMed ID: 10777146
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
    Valer L; de Mendoza C; Soriano V
    J Med Virol; 2005 Dec; 77(4):460-4. PubMed ID: 16254964
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Counteracting Akt Activation by HIV Protease Inhibitors in Monocytes/Macrophages.
    Pasquereau S; Kumar A; Abbas W; Herbein G
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29652795
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors.
    Jones SP; Janneh O; Back DJ; Pirmohamed M
    Antivir Ther; 2005; 10(2):207-13. PubMed ID: 15865214
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
    Côté HC; Brumme ZL; Harrigan PR
    J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human immunodeficiency virus type-1 (HIV-1) infection increases the sensitivity of macrophages and THP-1 cells to cytotoxicity by cationic liposomes.
    Konopka K; Pretzer E; Felgner PL; Düzgüneş N
    Biochim Biophys Acta; 1996 Jul; 1312(3):186-96. PubMed ID: 8703987
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of the human immunodeficiency virus-1 protease and human immunodeficiency virus-1 replication by bathocuproine disulfonic acid Cu1+.
    Davis DA; Branca AA; Pallenberg AJ; Marschner TM; Patt LM; Chatlynne LG; Humphrey RW; Yarchoan R; Levine RL
    Arch Biochem Biophys; 1995 Sep; 322(1):127-34. PubMed ID: 7574666
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Combination of phosphazide and crixivan inhibit replication of HIV-1 strains that are resistant to azidothymidine].
    Selimova LM; Kraevskiĭ AA; Galegov GA
    Dokl Akad Nauk; 1999 Dec; 369(6):847-9. PubMed ID: 10687056
    [No Abstract]   [Full Text] [Related]  

  • 60. Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages.
    Aquaro S; Svicher V; Ceccherini-Silberstein F; Cenci A; Marcuccilli F; Giannella S; Marcon L; Caliò R; Balzarini J; Perno CF
    J Antimicrob Chemother; 2005 Jun; 55(6):872-8. PubMed ID: 15845785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.